• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

泊沙康唑与两性霉素 B 在体外和体内对环孢菌属毛霉菌属侵袭性感染的活性比较:泊沙康唑疗效不佳。

In vitro and in vivo activities of posaconazole and amphotericin B in a murine invasive infection by Mucor circinelloides: poor efficacy of posaconazole.

机构信息

Unitat de Microbiologia, Facultat de Medicina i Ciències de la Salut, IISPV, Universitat Rovira i Virgili, Reus, Spain.

出版信息

Antimicrob Agents Chemother. 2012 May;56(5):2246-50. doi: 10.1128/AAC.05956-11. Epub 2012 Jan 30.

DOI:10.1128/AAC.05956-11
PMID:22290952
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3346623/
Abstract

The in vitro susceptibility of 17 strains of Mucor circinelloides to amphotericin B and posaconazole was ascertained by using broth microdilution and disk diffusion methods and by determining the minimal fungicidal concentration (MFC). We evaluated the efficacy of posaconazole at 40 mg/kg of body weight/day and amphotericin B at 0.8 mg/kg/day in a neutropenic murine model of disseminated infection by M. circinelloides by using 6 different strains tested previously in vitro. In general, most of the posaconazole MICs were within the range of susceptibility or intermediate susceptibility, while the small inhibition zone diameters (IZDs) were indicative of nonsusceptibility for all isolates tested. The MFCs were ≥ 3 dilutions higher than the corresponding MICs. In contrast, amphotericin B showed good activity against all of the strains tested regardless of the method used. The in vivo studies demonstrated that amphotericin B was effective in prolonging survival and reducing the fungal load. Posaconazole showed poor in vivo efficacy with no correlation with the MIC values. The results suggested that posaconazole should be used with caution in the treatment of infections caused by Mucor circinelloides or by strains of Mucor not identified to the species level.

摘要

采用肉汤微量稀释法和纸片扩散法,以及测定最小杀菌浓度(MFC),确定了 17 株环孢菌对两性霉素 B 和泊沙康唑的体外药敏性。我们通过使用先前在体外测试的 6 种不同菌株,评估了泊沙康唑(40mg/kg/天)和两性霉素 B(0.8mg/kg/天)在中性粒细胞减少症小鼠播散性环孢菌感染模型中的疗效。总的来说,大多数泊沙康唑 MIC 处于敏感或中介范围,而所有测试菌株的小抑菌环直径(IZD)表明均为非敏感性。MFC 比相应的 MIC 高 3 个稀释度。相比之下,两性霉素 B 对所有测试菌株均表现出良好的活性,无论使用哪种方法。体内研究表明,两性霉素 B 可有效延长生存时间并降低真菌负荷。泊沙康唑在体内疗效不佳,与 MIC 值无关。结果表明,在治疗环孢菌或未鉴定到种水平的毛霉属菌株引起的感染时,应谨慎使用泊沙康唑。

相似文献

1
In vitro and in vivo activities of posaconazole and amphotericin B in a murine invasive infection by Mucor circinelloides: poor efficacy of posaconazole.泊沙康唑与两性霉素 B 在体外和体内对环孢菌属毛霉菌属侵袭性感染的活性比较:泊沙康唑疗效不佳。
Antimicrob Agents Chemother. 2012 May;56(5):2246-50. doi: 10.1128/AAC.05956-11. Epub 2012 Jan 30.
2
Experimental murine model of disseminated infection by Saksenaea vasiformis: successful treatment with posaconazole.实验性播散性感染 Saksenaea vasiformis 的鼠模型:泊沙康唑治疗成功。
Med Mycol. 2012 Oct;50(7):710-5. doi: 10.3109/13693786.2012.673137. Epub 2012 Mar 29.
3
Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B.依柏呋喃酯在中性粒细胞减少症的肺部毛霉病的小鼠模型中具有疗效,无论是作为单一疗法还是与脂质体两性霉素 B 联合使用。
Antimicrob Agents Chemother. 2024 May 2;68(5):e0154523. doi: 10.1128/aac.01545-23. Epub 2024 Apr 1.
4
Efficacy of posaconazole in a murine model of disseminated infection caused by Apophysomyces variabilis.泊沙康唑在多变顶孢霉引起的播散性感染小鼠模型中的疗效。
J Antimicrob Chemother. 2012 Jul;67(7):1712-5. doi: 10.1093/jac/dks090. Epub 2012 Mar 16.
5
A Revised Species Concept for Opportunistic Species Reveals Species-Specific Antifungal Susceptibility Profiles.机会性致病物种的修订物种概念揭示了特定物种的抗真菌药敏谱。
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00653-19. Print 2019 Aug.
6
In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model.泊沙康唑在免疫抑制小鼠模型中对毛霉属真菌的体内活性。
Antimicrob Agents Chemother. 2002 Jul;46(7):2310-2. doi: 10.1128/AAC.46.7.2310-2312.2002.
7
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.泊沙康唑对小孢根霉致小鼠播散性感染的体外活性、血清水平与体内疗效的相关性研究。
Antimicrob Agents Chemother. 2009 Dec;53(12):5022-5. doi: 10.1128/AAC.01026-09. Epub 2009 Sep 28.
8
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.泊沙康唑在体外可增强两性霉素B对接合菌菌丝的活性。
Antimicrob Agents Chemother. 2008 Jul;52(7):2636-8. doi: 10.1128/AAC.00492-08. Epub 2008 May 5.
9
Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales.多中心评估最小抑菌浓度(MIC)分布以确定流行病学临界值,用于检测毛霉目中最具临床相关性的菌种对两性霉素B、泊沙康唑和伊曲康唑的耐药性。
Antimicrob Agents Chemother. 2015 Mar;59(3):1745-50. doi: 10.1128/AAC.04435-14. Epub 2015 Jan 12.
10
Alternative ergosterol biosynthetic pathways confer antifungal drug resistance in the human pathogens within the species complex.种复合体中的人类病原体中,替代麦角固醇生物合成途径赋予了抗真菌药物耐药性。
mBio. 2024 Aug 14;15(8):e0166124. doi: 10.1128/mbio.01661-24. Epub 2024 Jul 9.

引用本文的文献

1
Epidemiology, pathogenesis, clinical characteristics, and treatment of mucormycosis: a review.棘白菌素类药物在侵袭性曲霉菌病治疗中的作用。
Ann Med. 2024 Dec;56(1):2396570. doi: 10.1080/07853890.2024.2396570. Epub 2024 Sep 2.
2
Comparative evaluation of antifungal susceptibility testing methods for species isolates.不同菌种分离株抗真菌药敏试验方法的比较评估
Curr Med Mycol. 2023 Dec;9(4):47-50. doi: 10.22034/cmm.2024.345165.1480.
3
Experimental Models to Study the Pathogenesis and Treatment of Mucormycosis.用于研究毛霉病发病机制及治疗的实验模型
J Fungi (Basel). 2024 Jan 22;10(1):85. doi: 10.3390/jof10010085.
4
Characterization of the Sterol 24-C-Methyltransferase Genes Reveals a Network of Alternative Sterol Biosynthetic Pathways in .甾醇 24-C-甲基转移酶基因的特征分析揭示了. 中替代甾醇生物合成途径的网络。
Microbiol Spectr. 2023 Jun 15;11(3):e0031523. doi: 10.1128/spectrum.00315-23. Epub 2023 Apr 10.
5
Current treatments against mucormycosis and future directions.当前针对毛霉病的治疗方法和未来方向。
PLoS Pathog. 2022 Oct 13;18(10):e1010858. doi: 10.1371/journal.ppat.1010858. eCollection 2022 Oct.
6
Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India.COVID-19 相关肺毛霉菌病的定义、诊断和管理:印度真菌感染研究论坛和肺病科学院的德尔菲共识声明。
Lancet Infect Dis. 2022 Sep;22(9):e240-e253. doi: 10.1016/S1473-3099(22)00124-4. Epub 2022 Apr 4.
7
Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections.抗真菌药敏试验在侵袭性真菌感染管理中的作用及解读
J Fungi (Basel). 2020 Dec 30;7(1):17. doi: 10.3390/jof7010017.
8
Therapeutic Challenges of Non- Invasive Mold Infections in Immunosuppressed Patients.免疫抑制患者的非侵袭性霉菌感染的治疗挑战。
Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.01244-19. Print 2019 Nov.
9
Biodistribution and histopathology studies of amphotericin B sodium deoxycholate sulfate formulation following intratracheal instillation in rat models.两性霉素 B 去氧胆酸钠硫酸酯制剂经气管内滴注在大鼠模型中的生物分布和组织病理学研究。
Drug Deliv Transl Res. 2020 Feb;10(1):59-69. doi: 10.1007/s13346-019-00662-x.
10
Animal Models to Study Mucormycosis.用于研究毛霉病的动物模型。
J Fungi (Basel). 2019 Mar 27;5(2):27. doi: 10.3390/jof5020027.

本文引用的文献

1
Lessons from animal studies for the treatment of invasive human infections due to uncommon fungi.动物研究对治疗罕见真菌引起的侵袭性人类感染的启示。
J Antimicrob Chemother. 2011 Jul;66(7):1447-66. doi: 10.1093/jac/dkr143. Epub 2011 Apr 14.
2
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.在体和体内抗真菌药敏试验的毛霉科真菌毛霉。
Antimicrob Agents Chemother. 2010 Nov;54(11):4550-5. doi: 10.1128/AAC.00786-10. Epub 2010 Aug 30.
3
In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility.泊沙康唑对不同敏感性程度的接合菌的体外和体内活性。
J Antimicrob Chemother. 2010 Oct;65(10):2158-63. doi: 10.1093/jac/dkq276. Epub 2010 Jul 28.
4
Two new species of Mucor from clinical samples.从临床样本中分离到的两株新的毛霉属真菌。
Med Mycol. 2011 Jan;49(1):62-72. doi: 10.3109/13693786.2010.499521. Epub 2010 Jul 22.
5
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.泊沙康唑对体外活性与体内抗米根霉感染疗效的相关性研究。
Antimicrob Agents Chemother. 2010 May;54(5):1665-9. doi: 10.1128/AAC.01463-09. Epub 2010 Feb 9.
6
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.泊沙康唑对小孢根霉致小鼠播散性感染的体外活性、血清水平与体内疗效的相关性研究。
Antimicrob Agents Chemother. 2009 Dec;53(12):5022-5. doi: 10.1128/AAC.01026-09. Epub 2009 Sep 28.
7
Spectrum of zygomycete species identified in clinically significant specimens in the United States.在美国具有临床意义的标本中鉴定出的接合菌物种谱。
J Clin Microbiol. 2009 Jun;47(6):1650-6. doi: 10.1128/JCM.00036-09. Epub 2009 Apr 22.
8
Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.泊沙康唑、伏立康唑、伊曲康唑和两性霉素B对曲霉和根霉的体外活性比较以及根霉的协同试验。
Med Mycol. 2008 Sep;46(6):567-73. doi: 10.1080/13693780801975576.
9
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.泊沙康唑及其他抗真菌剂对通过内转录间隔区测序鉴定的毛霉目菌株的活性。
Antimicrob Agents Chemother. 2009 Apr;53(4):1686-9. doi: 10.1128/AAC.01467-08. Epub 2009 Jan 26.
10
Mucor circinelloides as a cause of invasive maxillofacial zygomycosis: an emerging dimorphic pathogen with reduced susceptibility to posaconazole.卷枝毛霉作为侵袭性颌面部接合菌病的病因:一种对泊沙康唑敏感性降低的新兴双相病原体。
J Clin Microbiol. 2009 Apr;47(4):1244-8. doi: 10.1128/JCM.02030-08. Epub 2009 Jan 26.